Project Grant R44HL160338
Award Date
4/1/25
Completion Date
12/31/26
Dollars Obligated
$1.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,267,886 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Shifa Biomedical Corporation in Malvern, PA. The funding supports executing IND-enabling studies for an oral PCSK9/LDLR antagonist drug candidate to treat hypercholesterolemia and reduce cardiovascular disease risk. Key activities include completing rat GLP toxicology, dog dose range finding, safety pharmacology, and FDA regulatory services to enable...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, provides funding to the University of South Florida to develop and evaluate novel small molecule compounds as potential treatments for heart failure.
The key products and services to be delivered under this $517,475 award, with a performance period from September 2024 to July 2026, include: 1) using medicinal chemistry, structure-activity...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,872 Project Grant (under CFDA 93.837 - Cardiovascular Diseases Research) to Novomedix LLC to develop novel small molecule therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. The key objectives are to: 1) Confirm the efficacy of Novomedix's lead drug candidates in advanced cell-based assays, 2) Scale up production of the lead candidates, and 3) Demonstrate...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,892 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Asclepia Technology LLC, a small business located in Sugar Land, Texas. The goal of this 12-month project is to develop a targeted cellular therapy for treating atherosclerotic vascular disease, a leading cause of death and disability. Specifically, the project will manufacture and test prototypes of dual-functional, echogenic immunoliposomes (DF-ELIP) that...
This $560,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support preclinical testing of a novel "triple gene therapy" approach to treat ischemic heart failure. The project, led by Baylor College of Medicine, aims to develop a less invasive procedure combining three complementary modalities: inducing existing cardiomyocyte proliferation, direct cardiac reprogramming of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc., a small business biotechnology company. The grant will fund the development of a compact, low-cost analytical device to precisely characterize lipoprotein particles in blood. This advanced technology will provide researchers and clinicians with new capabilities to evaluate cardiovascular disease risk and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $595,464 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cerulean Scientific Inc., a for-profit small business, to develop and optimize a tethered liquid perfluorocarbon (TLP) coating for peripheral vascular grafts. The goal is to improve outcomes for patients with critical limb ischemia by reducing complications such as thrombosis, neointimal hyperplasia, and biofilm formation that commonly lead to graft failure....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $689,232 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Louisville Office of Research & Innovation to investigate a dual-targeting compound for preventing doxorubicin-induced cardiotoxicity in cancer patients. Specifically, the research aims to optimize the compound's protective effects against cardiotoxicity in tumor-free and tumor-bearing mice, determine its mechanisms of...
This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of innovative in vitro assays to evaluate the efficacy and cytotoxicity of new atherosclerosis treatments. The awardee, Endomimetics LLC, is leveraging its proprietary nanomatrix cell sheet technology and "cell-as-glue" approach to create a 3D in vitro vascular sheet model of atherosclerosis. The goal...